In the last few years, we have focused on the search for new DMLs as potential antidiabetic agents by investigating 4-thiazolidinone derivatives targeting both protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), which are enzymes critically implicated in specific signalling alterations underlying the development of T2DM and its chronic complications [9,10,11]. Here, PTPN1 is linked to type 2 diabetes mellitus.